Oncology Modalities Facing Off: Room for Many or One to Rule them All?

Advanced Therapeutics
Wednesday, May 6, 2020 | 4:15 – 5:30 pm


  • Joel S. Sandler, PhD, Associate Principal, Cello Health BioConsulting, previously Defined Health


  • Michael DeRidder, PhD, VP, Medicine Commercialization Leader, Oncology Cell Therapy, GSK
  • Michael Kalos, PhD, EVP and Head of R&D, Arsenal Biosciences
  • Llew Keltner,MD, PhD, CEO, EPISTAT
  • Jason B. Litten, MD, CMO, Artiva Biotherapeutics
  • Vanessa Lucey, PhD, MBA, Director, CRI Venture Fund & Clinical Accelerator, Cancer Research Institute